SEC recommends Phase 1 trials of Reliance’s Covid vaccine candidate

The Subject Expert Committee (SEC) has recommended Phase 1 clinical trials of Reliance’s recombinant Covid-19 vaccine candidate.

Earlier, Mukesh Ambani-owned Reliance Life Sciences had sought approval for the Phase I trial of its proposed two-dose Covid-19 vaccine. The company received the approval during the SEC meeting on Friday.

Now, approval by the Drugs Controller General of India (DCGI) is required, following which Reliance Life Sciences can commence Phase 1 trials of the Covid-19 vaccine.

The company has proposed trials at ten sites in India, including centres in Tamil Nadu, Andhra, Maharashtra and Delhi.

The Covid-19 vaccine by Reliance Life Sciences will be a recombinant protein vaccine, similar to the Corbevax vaccine developed by Hyderabad-based Biological E, Business Insider reported on Friday.

So far, six vaccines have received Emergency Use Authorization (EUA) in India. This includes Zydus Cadila’s vaccine, Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, Moderna and Johnson & Johnson.

---

Credit: India Today | 27.08.2021